Patricia Almeida, DO
Pulmonary Disease · Miami, FLNPI 1760877641
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $927 and has fallen 69.2% since, to $285 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 22 payments — averaging $87.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$399
- AstraZeneca$257
- Mallinckrodt Enterprises LLC$243
- Boehringer Ingelheim$230
- Inari Medical, Inc.$192
- Genentech USA, Inc.$134
- plus $472 from 7 others
Across 43 payments — averaging $1912.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$82K
What the payments were for
- Food & beverage$1,928100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 2 | $399 |
| AstraZeneca | 3 | $257 |
| Mallinckrodt Enterprises LLC | 2 | $243 |
| Boehringer Ingelheim | 3 | $230 |
| Inari Medical, Inc. | 1 | $192 |
| Genentech USA, Inc. | 1 | $134 |
| Abiomed | 1 | $125 |
| Boston Scientific | 4 | $106 |
| Ceribell, Inc. | 1 | $91 |
| Grifols USA, LLC | 1 | $83 |
| Edwards Lifesciences | 1 | $29 |
| Pfizer | 1 | $23 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$243
- FASENRA$235
- RIBFIX BLU ADVANTAGE$200
- STERNALOCK BLU SYSTEM$199
- FLOWTRIEVER CATHETER, S$192
- CT THROMBECTOMY SYSTEM KIT$192
- XOLAIR$134
- Impella$125
How this compares
$1,928 in reported general payments places this provider in the 40th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.